SS
DRUG

Simplicity Solutions’s Bright Minds Biosciences DRUG Stock Holding History

Simplicity Solutions’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,241
Closed -$20.3K – 1088
2023
Q1 		$20.3K Buy
+9,241
New +$30.6K ﹤0.01% 1138

Other funds holding DRUG

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Simplicity Solutions's DRUG Position: Q2 2023 in Review

Simplicity Solutions sold out of Bright Minds Biosciences (DRUG) in Q2 2023, closing a stake of 9,241 shares — an estimated $20.3K sold.

Simplicity Solutions first reported a position in DRUG in Q1 2023 and held it in 1 quarter. The position peaked at $20.3K in Q1 2023. 8 funds tracked by Wall St. Rank hold DRUG as of Q2 2023.

  • Simplicity Solutions reported no remaining Bright Minds Biosciences position as of Q2 2023 after selling out during the quarter.
  • Simplicity Solutions sold 9,241 Bright Minds Biosciences shares in Q2 2023, an estimated $20.3K.
  • Simplicity Solutions first reported a position in Bright Minds Biosciences in Q1 2023 and held it in 1 quarter.
  • Simplicity Solutions's Bright Minds Biosciences position peaked at $20.3K in Q1 2023.
  • 8 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2023.

Based on Simplicity Solutions's 13F filing for Q2 2023, filed 26 Jul 2023.